BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Investor Relations
Stock price graph

We are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own partnerships of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). The Company has collaborated or is collaborating with Amgen, Pfizer, AstraZeneca, and Roche to develop Accurins based on therapeutic payloads from their product pipelines.

View all »   RSSRecent Releases

Aug 26, 2014
BIND Therapeutics to Present Data at the 26th EORTC-NCI-AACR Symposium

Aug 7, 2014
BIND Therapeutics Reports Second Quarter 2014 Financial Results

View all »Events & Presentations

Sep 3, 2014
Roche - Nature Biotechnology Symposium 2014: Unlocking Cell Transport Barriers to Deliver Large Molecule Therapeutics
Buonas, Switzerland

Oct 6, 2014
12th International Nanomedicine and Drug Delivery Symposium
Chapel Hill, NC

Oct 14, 2014
Partnerships in Drug Delivery
Boston, MA


NASDAQ: BIND
Price:
10.06
Change:
- 0.14
Day High:
10.28
Day Low:
9.94
Volume:
53,000
4:00 PM ET on Aug 29, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Media Inquiries
Direct media inquiries to:
Gina Nugent
The Yates Network
gina@theyatesnetwork.com

Investor Inquiries
Direct investor inquiries to:
Paul Cox
Stern Investor Relations
212-362-1200
BIND@sternir.com